Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Article

cited authors

  • Sulman, Erik P; Won, Minhee; Blumenthal, Deborah T; Vogelbaum, Michael A; Colman, Howard; Jenkins, Robert B; Chakravarti, Arnab; Jeraj, Robert; Brown, Paul D; Jaeckle, Kurt A; Schiff, David; Dignam, James; Atkins, James Norman; Brachman, David; Werner-Wasik, Maria; Komaki, Ritsuko; Gilbert, Mark R; Mehta, Minesh P; Aldape, Kenneth D

fiu authors

publication date

  • June 20, 2013

start page

  • lba2010

end page

  • lba2010

volume

  • 31

issue

  • 18_suppl